Discovery Data Pipeline
Acellera Therapeutics differential approach to drug discovery is reflected by a uniquely large pipeline of target data with high biological and disease validation.
Pipeline
Target
Target Class
Approach
Tested/Computed
Hit Identification
Hit-to-Lead
Orthosteric
83 / 109
18 hits (low μM IC50)
6 μM, 6 μM, 9 μM, 10 μM, 11 μM
Ortho & Allosteric
40 / 109
8 hits (low μM IC50)
40 nM, 85 nM
>1000 folds selective against RIPK1
Orthosteric
19 / 109
12 hits (low μM IC50)
378 nM, 619 nM, 866 nM, 905 nM
Orthosteric
32 / 109
8 hits (low μM IC50)
30 μM, 47 μM
Orthosteric
40 / 109
4 hits (low μM IC50)
5 μM, 24 μM
Orthosteric
40 / 109
2 hits (low μM IC50)
3 μM, 91 μM
Orthosteric
10 / 106
1 hit via NMR
-